Peter Schmid

24.3k citations

207 papers · 11.0k indexed · 11 hit papers · h-index 44

Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers 78
- Cancer Treatment and Pharmacology 59
- HER2/EGFR in Cancer Research 57
Cancer Research top 0.2%
- Breast Cancer Treatment Studies 36
- Cancer Genomics and Diagnostics 23
Immunology top 0.5%
Pulmonary and Respiratory Medicine top 0.5%
- Advanced Breast Cancer Therapies 111
- Lung Cancer Treatments and Mutations 16
- Prostate Cancer Treatment and Research 12
Genetics top 2%

Co-authors: Sherene Loi Hope S. Rugo Hiroji Iwata Eric P. Winer Sylvia Adams Carlos H. Barrios Leisha A. Emens Luciana Molinero
Cited by: Oncology Cancer Research Immunology
Journals: Journal of Clinical Oncology (45 papers)Cancer Research (44 papers)Annals of Oncology (40 papers)
Partner nations: United Kingdom United States Spain

In The Last Decade

Peter Schmid

197 papers receiving 10.9k citations

Hit Papers

11 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2025 New England Journal of Medicine
2024 Annals of Oncology
2022 New England Journal of Medicine
2021 EClinicalMedicine
2021 JNCI Journal of the National Cancer Institute
2021 The Lancet Oncology
2019 The Lancet Oncology
2018 New England Journal of Medicine
2018 Annals of Oncology
2018 JAMA Oncology
2018 Journal of Clinical Oncology

Peers

Countries citing papers authored by Peter Schmid

Since Specialization

Citations

This map shows the geographic impact of Peter Schmid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Schmid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Schmid more than expected).

Fields of papers citing papers by Peter Schmid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Schmid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Schmid. The network helps show where Peter Schmid may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter Schmid, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Schmid Line = papers co-authored together Peter Schmid links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522breakdown → Annals of Oncology ·Lajos Pusztai,Carsten Denkert,Joyce O’Shaughnessy,Javier Cortés,Rebecca Dent,Heather L. McArthur,Sherko Kümmel,Jonas Bergh,Y.H. Park,Rina Hui,Nadia Harbeck,Masato Takahashi,Michael Untch,Peter A. Fasching,Fátima Cardoso,Ying Zhu,Wilbur Pan,Konstantinos Tryfonidis,Peter Schmid	2024	47
2	LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial Annals of Oncology ·Peter Schmid,Heather L. McArthur,Maria Margarida de Carvalho Neta,Baojun Xu,Jongin Son,Sella Ridha Agfiani,Utkan Demirci,Ulrike Passern,Jaya Ghosh,Roberto Hegg,Hiroaki Iwata,Yamil Alonso Lopez Chuken,M. Nechaeva,Mark E. Robson,Ricardo Villalobos-Valencia,Andrew Lloyd,Celina M. D’Cruz,Andrew Foxley,Y.H. Park	2024	5
3	First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. Journal of Clinical Oncology ·Dejan Juric,Kevin Kalinsky,Nicholas C. Turner,Komal Jhaveri,Peter Schmid,Sherene Loi,Cristina Saura,Seock‐Ah Im,Patrapim Sunpaweravong,Huiping Li,Antonino Musolino,Qingyuan Zhang,Zbigniew Nowecki,Roland Leung,Eirini Thanopoulou,В Б Митюхляев,Guiyuan Lei,Jacob Devine,Thomas J. Stout,Sibylle Loibl	2024	23
4	Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer ESMO Open ·Charles M. Rudin,Andrés Cervantes,Afshin Dowlati,Benjamin Besse,Bing Ma,Daniel B. Costa,Peter Schmid,Rebecca S. Heist,Victoria Villaflor,Jessica Spahn,DJ Donaghy,Edward Cha,Gregory J. Riely,Scott Gettinger	2023	8
5	LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study Annals of Oncology ·Peter Schmid,Javier Cortés,Rebecca Dent,Lajos Pusztai,Heather L. McArthur,Sherko Kümmel,Carsten Denkert,Y.H. Park,Rina Hui,Isaac Appleton Jewett,保治川合,Theodoros Foukakis,Saniya,Brian D. Newbury,S-A. Im,Fátima Cardoso,Yu Ding,Elke Röder,Konstantinos Tryfonidis,Joyce O’Shaughnessy	2023	20
6	LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer Annals of Oncology ·Fátima Cardoso,Heather L. McArthur,Peter Schmid,Javier Cortés,Nadia Harbeck,Melinda L. Telli,David W. Cescon,Joyce O’Shaughnessy,Peter A. Fasching,Zhi-Min Shao,Delphine Loirat,Y.H. Park,J. Galant,E. V. Martinez,Hiroyuki Yasojima,Yu Ding,M. Sibbari,Vassiliki Karantza,Konstantinos Tryfonidis,Aditya Bardia	2023	67
7	Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355 JNCI Journal of the National Cancer Institute ·David W. Cescon,Peter Schmid,Hope S. Rugo,Seock‐Ah Im,Mastura Md Yusof,Carlos Gallardo,Oleg Lipatov,Carlos H. Barrios,José Manuel Pérez-García,Hiroji Iwata,Norikazu Masuda,Marco Torregroza Otero,Erhan Gökmen,Sherene Loi,Amin Haiderali,Xuan Zhou,Zifang Guo,Allison Martin Nguyen,Javier Cortés	2023	7
8	194P Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC) ESMO Open ·Frederik Marmé,Hope S. Rugo,Sara M. Tolaney,Aditya Bardia,Peter Schmid,Wendy Verret,T. Valdez,F. Ssegujja,Javier Cortés	2023	9
9	ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer Future Oncology ·Sara A. Hurvitz,Thomas Bachelot,Giampaolo Bianchini,Nadia Harbeck,Sherene Loi,Yeon Hee Park,Aleix Prat,Leslie Gilham,Thomas Boulet,Simbarashe Musaka,Estefanía Monturus,Chiara Lambertini,Karen Telling,Adam Knott,Eleonora Restuccia,Peter Schmid	2022	15
10	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer European Journal of Cancer ·Ángela Quintana,Vicente Peg,Aleix Prat,Teresa Moliné,Guillermo Villacampa,Laia Paré,Patricia Galván,俊太郎小山,Peter Schmid,Giuseppe Curigliano,Eva Muñoz‐Couselo,José Manuel Pérez-García,Mercè Martı́,Una H. Arapović,Carla Anjos Souza,Miguél Vázquez,Leticia De Mattos‐Arruda,Javier Cortés	2021	12
11	Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial European Journal of Cancer ·José Manuel Pérez-García,Antonio Llombart‐Cussac,María Gión,Giuseppe Curigliano,Е.М. БЕГИШЕВ,José Luis Alonso-Romero,Begoña Bermejo,Lourdes Calvo,Vicente Carañana,А.Ф. Торонджадзе,Dhanashree S. Ghadge,Aleix Prat,Manuel Ruíz Borrego,Miguel Sampayo-Cordero,Miguel Ángel Seguí,H Colson,Andrea Malfettone,Peter Schmid,Javier Cortés	2021	30
12	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis Cancer Research ·Min Huang,Joyce O’Shaughnessy,Jing Zhao,Amin Haiderali,Javier Cortés,Scott D. Ramsey,Andrew Briggs,Enrique Roldán González,Vassiliki Karantza,Gursel Aktan,Cynthia Z. Qi,Chenyang Gu,Jipan Xie,Алексей Анатольевич Лялинский,John S. Cook,Michael Untch,Peter Schmid,Peter A. Fasching	2020	89
13	Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC) Cancer Research ·Peter Schmid,Delphine Loirat,Peter Savas,Enrique Espinosa,Valentina Boni,Antoîne Italiano,Shane White,Stina Mui Singel,Nimali P. Withana,Aruna Mani,Suwen Li,磯雄恒川,Matthew Wongchenko,Yiqiang He	2019	42
14	Systematic review of the impact of breast‐conserving surgery on cancer outcomes of multiple ipsilateral breast cancers BJS Open ·Zoë Winters,Jonathan Horsnell,Karen T Elvers,Anthony Maxwell,J. Louise Jones,Abeer M. Shaaban,Peter Schmid,Norman Williams,Andrew D Beswick,Rosemary Greenwood,Jenny Ingram,Christobel Saunders,Jayant S. Vaidya,Laura J. Esserman,Ismail Jatoi,Adrian Murray Brunt	2018	24
15	Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses Cancer Research ·Peter Schmid,Cristina Cruz,Fadi S. Braiteh,Joseph P. Eder,Sara M. Tolaney,Irene Kuter,Rita Nanda,Cathie T. Chung,Philippe A. Cassier,Jean‐Pierre Delord,Michael S. Gordon,Yijin Li,Bo Liu,Carol O’Hear,Marcella Fassò,Luciana Molinero,Leisha A. Emens	2017	92
16	Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. Journal of Clinical Oncology ·Peter Schmid,Yeon Hee Park,Eva Muñoz‐Couselo,Sung‐Bae Kim,Joohyuk Sohn,Seock‐Ah Im,Esther Holgado,Yang Wang,Thao P. Dang,Gursel Aktan,Javier Cortés	2017	68
17	Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. Journal of Clinical Oncology ·Sylvia Adams,Sherene Loi,Deborah Toppmeyer,David W. Cescon,Michelino De Laurentiis,Rita Nanda,Eric P. Winer,Hirofumi Mukai,Kenji Tamura,Anne Armstrong,Minetta C. Liu,Hiroji Iwata,Larisa Ryvo,Pauline Wimberger,Deborah Card,Yu Ding,Vassiliki Karantza,Peter Schmid	2017	55
18	A Review of Fulvestrant in Breast Cancer Oncology and Therapy ·Mark R. Nathan,Peter Schmid	2017	128
19	The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies Cancer Treatment Reviews ·Javier Cortés,Seock‐Ah Im,Esther Holgado,José Manuel Pérez-García,Peter Schmid,Mariana Chávez‐MacGregor	2017	35
20	Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer Cancer Research ·Nelofer Syed,Helen M. Coley,Jalid Sehouli,Dominique Koensgen,Alexander Mustea,Peter W. Szlosarek,Iain A. McNeish,Sarah P. Blagden,Peter Schmid,David P. Lovell,Eleftheria Hatzimichael,Tim Crook	2011	49

About Peter Schmid

Peter Schmid is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 207 papers that have together received 11.0k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (111 papers), Cancer Immunotherapy and Biomarkers (78 papers), Cancer Treatment and Pharmacology (59 papers), HER2/EGFR in Cancer Research (57 papers), Breast Cancer Treatment Studies (36 papers), Cancer Genomics and Diagnostics (23 papers), Lung Cancer Treatments and Mutations (16 papers) and Prostate Cancer Treatment and Research (12 papers). The work is most often cited by research in Oncology (8.3k citations), Cancer Research (3.2k citations) and Immunology (2.6k citations). Peter Schmid has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Sherene Loi, Hope S. Rugo, Hiroji Iwata, Eric P. Winer, Sylvia Adams, Carlos H. Barrios, Leisha A. Emens, Luciana Molinero, Véronique Dièras and Jane Yuet Ching Hui. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, ESMO Open and Future Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact